It may not match what you are looking for, but here's a letter I sent to USNU ($1.5M market cap) a few days ago.
To the board and management team of US NeuroSurgical Holdings:
As a fellow shareholder, I would like to share my thoughts on the direction of the company.
Congratulations to your team on the positive results from the NYU Medical Center over the last few years. Relative to its market cap, the company has substantial assets and expected short-term cash flows. By my estimation the company is currently worth about $0.55 per share, compared to a current share price of $0.17.
However, I believe that if the company continues to invest in and loan money to its subsidiaries, it will have a negative impact on shareholder value. This is especially critical since the company has advanced $2M to subsidiaries over the last year.
As you know, all of the joint ventures except BOPRE have a negative equity position and all except CGK are currently unprofitable. This makes these companies extremely shaky credit risks, and I question whether US Neurosurgical is earning an appropriate interest rate on these loans. Although it is somewhat early to assess the results at MOP and CBOP, the initial investments in FOP and CGK were made 9 and 12 years ago. It appears that US NeuroSurgical’s return on these investments has been unsatisfactory.
Instead of continuing to invest in these subsidiaries, which do not appear to offer an attractive risk/reward, I believe the company should return excess cash to shareholders. Furthermore, the company is too small to justify the expense of being public. The most appropriate action would be to sell the company or sell the remaining assets and distribute the proceeds to shareholders when the NYU operations wind down.
Please let me know your thoughts on this subject.
Sincerely,
Nathan Herold
My math:
$4.5M current assets
$2.3M operating cash flow per year x 20 months = $3.8M
-$3.5M liabilities
Total: $4.8M